新型冠狀病毒

Covid-19 shot accelerates vaccine technology

A look inside the groundbreaking mRNA science underpinning the BioNTech-Pfizer treatment

The news that BioNTech and Pfizer’s Covid-19 vaccine was more than 90 per cent effective in clinical trials has sparked new hope that vaccinations will provide a way out of the coronavirus pandemic.

“The good message for mankind is that we now understand that Covid-19 can be prevented by a vaccine,” Ugur Sahin, BioNTech’s chief executive, said after the announcement.

The phase 3 trial still has to be completed and the data submitted to regulators for approval, but the initial results for the shot, which uses groundbreaking mRNA technology, were a significant milestone in the hunt of a vaccine.

您已閱讀11%(598字),剩餘89%(5096字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×